Background Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD), and ...
On Wednesday, FibroBiologics, Inc. (NASDAQ: FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO). The patent application covers a proprietary fibroblast-derived ...
Fibrosis is the body's way of patching up damage—a bit like fixing a pothole. When skin is cut or a muscle is injured, ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Advancing Fibroblast Therapy on Multiple Fronts In the past month, ...
Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...
Researchers develop a 3D cell culture system to test how inhibiting fibroblast activities can help treat lung cancer. To simulate the tumor microenvironment and mimic real tissues, the team ...
FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results